NASDAQ:RKDA Arcadia Biosciences (RKDA) Stock Price, News & Analysis $2.91 +0.24 (+9.14%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Arcadia Biosciences Stock (NASDAQ:RKDA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Arcadia Biosciences alerts:Sign Up Key Stats Today's Range$2.72▼$2.9250-Day Range$2.67▼$5.2752-Week Range$1.85▼$10.31Volume4,989 shsAverage Volume310,380 shsMarket Capitalization$3.89 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingStrong Buy Company OverviewArcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.Read More… Remove Ads Arcadia Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreRKDA MarketRank™: Arcadia Biosciences scored higher than 65% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingArcadia Biosciences has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageArcadia Biosciences has received no research coverage in the past 90 days.Read more about Arcadia Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcadia Biosciences is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcadia Biosciences is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcadia Biosciences has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Arcadia Biosciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.76% of the float of Arcadia Biosciences has been sold short.Short Interest Ratio / Days to CoverArcadia Biosciences has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arcadia Biosciences has recently decreased by 16.94%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcadia Biosciences does not currently pay a dividend.Dividend GrowthArcadia Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.76% of the float of Arcadia Biosciences has been sold short.Short Interest Ratio / Days to CoverArcadia Biosciences has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arcadia Biosciences has recently decreased by 16.94%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.50 News SentimentArcadia Biosciences has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Basic Materials companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Arcadia Biosciences this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Arcadia Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Arcadia Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,743.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.80% of the stock of Arcadia Biosciences is held by insiders.Percentage Held by InstitutionsOnly 17.73% of the stock of Arcadia Biosciences is held by institutions.Read more about Arcadia Biosciences' insider trading history. Receive RKDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RKDA Stock News HeadlinesArcadia Biosciences (NASDAQ:RKDA) Coverage Initiated by Analysts at StockNews.comApril 1 at 1:37 AM | americanbankingnews.comArcadia Biosciences, Inc. (NASDAQ:RKDA) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | msn.comDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.April 3, 2025 | Altimetry (Ad)Arcadia Biosciences outlines 2025 growth potential for Zola after 46% sales increase in 2024March 21, 2025 | msn.comArcadia Biosciences, Inc (RKDA) Q4 2024 Earnings Call TranscriptMarch 20, 2025 | seekingalpha.comArcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2024 Financial Results and Business HighlightsMarch 20, 2025 | businesswire.comArcadia Biosciences Q4 Earnings PreviewMarch 19, 2025 | msn.comArcadia Biosciences (RKDA) Announces Date of Fourth Quarter 2024 Financial Results and Business Highlights Conference CallMarch 6, 2025 | businesswire.comSee More Headlines RKDA Stock Analysis - Frequently Asked Questions How have RKDA shares performed this year? Arcadia Biosciences' stock was trading at $5.92 at the beginning of 2025. Since then, RKDA stock has decreased by 51.9% and is now trading at $2.8450. View the best growth stocks for 2025 here. How were Arcadia Biosciences' earnings last quarter? Arcadia Biosciences, Inc. (NASDAQ:RKDA) released its quarterly earnings data on Tuesday, August, 13th. The basic materials company reported $0.78 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.27 by $0.49. The basic materials company earned $1.31 million during the quarter, compared to analysts' expectations of $0.95 million. Arcadia Biosciences had a negative net margin of 110.61% and a negative trailing twelve-month return on equity of 52.63%. When did Arcadia Biosciences' stock split? Shares of Arcadia Biosciences reverse split on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Arcadia Biosciences IPO? Arcadia Biosciences (RKDA) raised $66 million in an IPO on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO. How do I buy shares of Arcadia Biosciences? Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcadia Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcadia Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), PayPal (PYPL), General Electric (GE), Arista Networks (ANET), Advanced Micro Devices (AMD) and CrowdStrike (CRWD). Company Calendar Last Earnings8/13/2024Today4/03/2025Next Earnings (Estimated)5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBasic Materials Industry Agricultural production - crops Sub-IndustryAgriculture Current SymbolNASDAQ:RKDA CIK1469443 Webwww.arcadiabio.com Phone(530) 756-7077Fax530-756-7027Employees60Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+118.6%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($4.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,980,000.00 Net Margins-110.61% Pretax Margin-156.15% Return on Equity-52.63% Return on Assets-34.57% Debt Debt-to-Equity RatioN/A Current Ratio4.60 Quick Ratio4.24 Sales & Book Value Annual Sales$5.05 million Price / Sales0.74 Cash FlowN/A Price / Cash FlowN/A Book Value$11.44 per share Price / Book0.24Miscellaneous Outstanding Shares1,367,000Free Float1,340,000Market Cap$3.75 million OptionableNot Optionable Beta0.78 Social Links 10 Stocks Set to Soar in Spring 2025Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.Get This Free Report This page (NASDAQ:RKDA) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcadia Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcadia Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.